Category

Events
Webinar title: Liquid-based Detection of Copy Number Variations (CNVs) in Cancer Date: Wednesday, April 6, 2021 Duration: 32 minutes The liquid biopsy landscape (CNVs) is changing rapidly. Predicine is advancing the clinical utility of liquid biopsy more broadly across the continuum of cancer care. We are innovating our liquid biopsy technology to detect a range of...
Webinar title: Liquid-based Detection of Copy Number Variations (CNVs) in Cancer Date: Tuesday, April 6, 2021 Duration: 40 minutes Copy number variations (CNVs) are often correlated with negative outcomes for cancer patients, however they are challenging to detect in liquid biopsy samples. Improvements in next generation sequencing (NGS) technology is enhancing the possibility of detecting these deleterious...
Webinar title: Urine-based NGS liquid biopsy applications in bladder cancer Date: Tuesday, March 23, 2021 Duration: 40 minutes Speaker: Bonnie King, PhD, Associate Director of Translational Medicine, Predicine, Inc. Urine-based liquid biopsy is showing signs of great promise for profiling urothelial malignancies, which shed DNA directly into urine. Predicine and collaborators recently presented work at ASCO-GU 2021 demonstrating...
Predicine is excited to partner with Canadian Cancer Trials Group (CCTG) and contribute to a 2021 Gastrointestinal Cancers Symposium featured presentation in pancreatic cancer. PredicineATLAS, a 600-gene cfDNA assay, is utilized in the CCTG PA.7 trial to assess the predictive value of plasma TMB which demonstrated predictive of benefit from the addition of AstraZeneca’s dual...
Predicine will host a satellite symposium at the 2020 International Society of Liquid Biopsy (ISLB) Virtual Congress to discuss the clinical utility of circulating cell-free DNA and RNA liquid biopsy tests with a focus on MRD and early cancer detection. This symposium will bring together biomarker experts from Merck KGaA, Darmstadt, Germany, Washington University, and...
Predicine is excited to partner with Canadian Cancer Trials Group (CCTG) and contribute to a European Society for Medical Oncology (ESMO) featured presentation in pancreatic cancer. PredicineATLAS, a 600-gene cfDNA assay, is utilized in the CCTG PA.7 trial to assess the predictive value of blood TMB in metastatic pancreatic ductal adenocarcinoma patients treated with Durvalumab...
Date: June 22-24, 2020 Location: Virtual   Predicine will present three e-posters focusing on liquid biopsy methylation, urine biomarkers, and cfDNA+cfRNA molecular profiling, at the American Association for Cancer Research Virtual Meeting II, taking place June 22-24, 2020. For the first time, Predicine will present its proprietary methylation cell-free DNA (cfDNA) liquid biopsy technology for...
Date: May 29 – 31, 2020 Location: Virtual   In collaboration with Northwestern University and Peking University Cancer Hospital, we are presenting a poster at the American Society of Clinical Oncology Virtual Scientific Program. This study demonstrates that PredicineCARE blood-based ctDNA effectively detected the key mutations in HR+ metastatic breast cancer patients in US and...
Date: March 1-4, 2020 Location: Moscone South Convention Center, San Francisco, CA  Attend our presentation or schedule a meeting with us here. Presentation: Blood and Urine-based Liquid Biopsy Solutions for TMB and MRD in Clinical Trials In this talk, we’ll present the development and clinical applications of blood and urine-based liquid biopsy solutions using cfDNA...
Date: February 13 – 15, 2020 Location: Moscone West Building, San Francisco, CA  In collaboration with Mayo Clinic, Lee Moffitt Cancer Center, Monash University, and Kintor Pharmaceuticals, we are proud to announce our 3 abstracts in prostate cancer at the American Society of Clinical Oncology – Genitourinary Cancers Symposium.  Stop by our poster presentations or...
1 2